- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000895
A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection
Pathogenesis of MAC Disease in Advanced HIV-1-Infected Subjects and the Impact of Highly-Active Antiretroviral Treatment (HAART) on Immune Functions Relevant for MAC and Other Opportunistic Infections
The purpose of this study is to determine if infection with Mycobacterium avium complex (MAC) occurs in other parts of the body before it is found in the blood. This study also evaluates the relationships between the amount of HIV in the blood, immune system functions, and the presence of MAC infection.
HIV-positive patients are at risk for MAC infection because their immune systems have been weakened by HIV. It is hoped that aggressive treatment with anti-HIV drugs may improve their immune systems enough to prevent against MAC.
Study Overview
Status
Intervention / Treatment
Detailed Description
The intent of this study is to define more precisely the natural history and immunopathogenesis of MAC disease in the HIV-infected population. It is suggested that MAC disease in AIDS patients results both from specific immunologic deficiencies caused by HIV infection of the host and as a result of specific mycobacterial virulence properties. Therefore, aggressive antiretroviral drug treatment of HIV-infected patients at risk for DMAC due to specific immune deficiencies will improve these immune functions in such a manner as to resist DMAC.
A total of 85 patients will be stratified at baseline into one of three groups:
Group I - 40 patients at high risk for MAC infection are neither followed beyond baseline nor receive study treatment.
Group II - 15 patients with DMAC, i.e., newly diagnosed MAC-bacteremic patients with no more than 72 hours prior treatment for MAC, receive individualized regimen of HAART for 48 weeks: nelfinavir (NEV), nevirapine (NVP), and nucleoside reverse transcriptase inhibitor(s) as per primary physician. Patients are evaluated through clinical, microbiologic, and virologic assessments, and intensive immunologic evaluations at Weeks 12, 24, and 48.
Group III - 30 asymptomatic HIV-infected patients are further stratified (15 patients/stratum) by CD4 count (less than or equal to 50 cells/mm3 or 100-250 cells/mm3). Patients in Group III follow the same HAART regimen and evaluations as Group II patients and continue evaluations for up to 48 weeks, if an acceptable response is found within 12 weeks of entry. Patients in Stratum 1 of Group III receive MAC prophylaxis with azithromycin once weekly with follow-up evaluations as in Group II. Patients in Group III that have a positive MAC blood or bone marrow culture at any time during the study will, from that point on, follow the same schedule of evaluations as patients in Group II.
[AS PER AMENDMENT 11/3/98: Up to 100 evaluable patients will now be studied. Group 2 is now modified to include up to an additional 15 evaluable patients with known MAC bacteremia and less than or equal to 7 days prior MAC treatment who are unable to commit to long-term follow-up (Group 2b); these patients will undergo only baseline evaluations. Group 2a consists of 15 evaluable patients with known MAC bacteremia and less than or equal to 7 days of prior MAC treatment who are willing and able to enter the follow-up phase.]
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Univ of Alabama at Birmingham
-
-
California
-
Los Angeles, California, United States, 900331079
- Univ of Southern California / LA County USC Med Ctr
-
San Diego, California, United States, 921036325
- Univ of California / San Diego Treatment Ctr
-
Stanford, California, United States, 943055107
- Stanford Univ Med Ctr
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20059
- Howard Univ
-
-
Florida
-
Miami, Florida, United States, 331361013
- Univ of Miami School of Medicine
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory Univ
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Univ Med School
-
Chicago, Illinois, United States, 60612
- Rush Presbyterian - Saint Luke's Med Ctr
-
Chicago, Illinois, United States, 60612
- Cook County Hosp
-
-
Indiana
-
Indianapolis, Indiana, United States, 462025250
- Indiana Univ Hosp
-
Indianapolis, Indiana, United States, 46202
- Division of Inf Diseases/ Indiana Univ Hosp
-
-
New York
-
Buffalo, New York, United States, 14215
- SUNY / Erie County Med Ctr at Buffalo
-
New York, New York, United States, 10003
- Beth Israel Med Ctr
-
New York, New York, United States, 10016
- Bellevue Hosp / New York Univ Med Ctr
-
New York, New York, United States, 10021
- St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr
-
Rochester, New York, United States, 14642
- Univ of Rochester Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 452670405
- Univ of Cincinnati
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve Univ
-
Columbus, Ohio, United States, 432101228
- Ohio State Univ Hosp Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Univ of Pennsylvania at Philadelphia
-
-
South Carolina
-
West Columbia, South Carolina, United States, 29169
- Julio Arroyo
-
-
Texas
-
Dallas, Texas, United States, 75390
- Univ of Texas, Southwestern Med Ctr of Dallas
-
Dallas, Texas, United States, 75235
- Univ of Texas Southwestern Med Ctr of Dallas
-
Galveston, Texas, United States, 775550435
- Univ of Texas Galveston
-
-
Washington
-
Seattle, Washington, United States, 98104
- Univ of Washington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
You may be eligible for this study if you:
- Are HIV-positive.
- Have a CD4 count under 50 cells/mm3 or between 100 and 250 cells/mm3 within 30 days of study entry.
- Have at least one symptom (e.g., fever, diarrhea, or weight loss) suggestive of MAC infection.
- Have MAC infection with 7 days or less of MAC treatment.
- Have an HIV blood level greater than 10,000 copies/ml within 30 days of study entry.
- Are 18 years of age or older.
Exclusion Criteria
You will not be eligible for this study if you:
- Have any active infection (except for MAC in Group 2 patients) or any cancer.
- Are unable to follow an acceptable anti-HIV drug regimen (Groups 2 and 3).
- Are pregnant or breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Investigators
- Study Chair: Rob Roy MacGregor
Publications and helpful links
Study record dates
Study Major Dates
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease Attributes
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Parasitic Diseases
- Slow Virus Diseases
- Mycobacterium Infections, Nontuberculous
- HIV Infections
- Infections
- Communicable Diseases
- Mycobacterium Infections
- Acquired Immunodeficiency Syndrome
- Mycobacterium avium-intracellulare Infection
- Opportunistic Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Nevirapine
- Azithromycin
- Nelfinavir
Other Study ID Numbers
- ACTG 341
- 11312 (Registry Identifier: DAIDS ES)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
Clinical Trials on Nevirapine
-
Boehringer IngelheimCompletedHIV InfectionsUnited States, Botswana, Germany, South Africa
-
Boehringer IngelheimCompletedHIV InfectionsUnited States, Argentina, Australia, Belgium, Botswana, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Russian Federation, South Africa, Spain, Switzerland, United Kingdom
-
Boehringer IngelheimCompletedHIV InfectionsUnited States, France, Germany, United Kingdom
-
Boehringer IngelheimCompleted
-
Peking Union Medical CollegeMinistry of Science and Technology of the People´s Republic of ChinaCompleted
-
Boehringer IngelheimCompleted
-
Makerere UniversityUniversity of LiverpoolCompletedHIV Infections | TuberculosisUganda
-
Boehringer IngelheimCompletedHIV InfectionsArgentina, Germany, Italy, Mexico, Poland, Portugal, Romania, Spain, Switzerland, United Kingdom
-
Elim Pediatric Pharmaceuticals Inc.Unknown